nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—SLC6A3—Parkinson's disease	0.345	0.476	CbGaD
Atomoxetine—HTR2A—Parkinson's disease	0.198	0.274	CbGaD
Atomoxetine—CYP2D6—Parkinson's disease	0.181	0.25	CbGaD
Atomoxetine—SLC6A2—locus ceruleus—Parkinson's disease	0.00555	0.0515	CbGeAlD
Atomoxetine—HTR2A—enteric nervous system—Parkinson's disease	0.00505	0.0469	CbGeAlD
Atomoxetine—NPY1R—nerve—Parkinson's disease	0.00489	0.0454	CbGeAlD
Atomoxetine—SLC6A2—sympathetic nervous system—Parkinson's disease	0.00439	0.0407	CbGeAlD
Atomoxetine—HTR2A—myenteric nerve plexus—Parkinson's disease	0.00383	0.0356	CbGeAlD
Atomoxetine—HTR2A—locus ceruleus—Parkinson's disease	0.00334	0.031	CbGeAlD
Atomoxetine—HTR1B—telencephalic ventricle—Parkinson's disease	0.00329	0.0305	CbGeAlD
Atomoxetine—SLC6A3—telencephalic ventricle—Parkinson's disease	0.00326	0.0303	CbGeAlD
Atomoxetine—HTR1D—telencephalic ventricle—Parkinson's disease	0.00318	0.0296	CbGeAlD
Atomoxetine—HTR2C—telencephalic ventricle—Parkinson's disease	0.00315	0.0293	CbGeAlD
Atomoxetine—SLC6A2—autonomic nervous system—Parkinson's disease	0.00295	0.0274	CbGeAlD
Atomoxetine—HTR2A—cerebellar cortex—Parkinson's disease	0.00272	0.0252	CbGeAlD
Atomoxetine—HTR2A—sympathetic nervous system—Parkinson's disease	0.00264	0.0245	CbGeAlD
Atomoxetine—SLC6A3—nerve—Parkinson's disease	0.00206	0.0191	CbGeAlD
Atomoxetine—NPY1R—forebrain—Parkinson's disease	0.00202	0.0188	CbGeAlD
Atomoxetine—HTR2A—pons—Parkinson's disease	0.00192	0.0178	CbGeAlD
Atomoxetine—HTR2A—autonomic nervous system—Parkinson's disease	0.00177	0.0165	CbGeAlD
Atomoxetine—SLC6A2—nerve—Parkinson's disease	0.00166	0.0154	CbGeAlD
Atomoxetine—HTR2A—telencephalic ventricle—Parkinson's disease	0.00158	0.0147	CbGeAlD
Atomoxetine—SLC6A3—hindbrain—Parkinson's disease	0.00154	0.0143	CbGeAlD
Atomoxetine—HTR6—forebrain—Parkinson's disease	0.00142	0.0132	CbGeAlD
Atomoxetine—SLC6A4—hindbrain—Parkinson's disease	0.00141	0.0131	CbGeAlD
Atomoxetine—HTR2A—peripheral nervous system—Parkinson's disease	0.00128	0.0119	CbGeAlD
Atomoxetine—NPY1R—head—Parkinson's disease	0.00116	0.0108	CbGeAlD
Atomoxetine—NPY1R—nervous system—Parkinson's disease	0.0011	0.0102	CbGeAlD
Atomoxetine—NPY1R—central nervous system—Parkinson's disease	0.00106	0.00982	CbGeAlD
Atomoxetine—HTR2A—nerve—Parkinson's disease	0.000997	0.00926	CbGeAlD
Atomoxetine—HTR1B—brainstem—Parkinson's disease	0.00089	0.00826	CbGeAlD
Atomoxetine—SLC6A3—brainstem—Parkinson's disease	0.000883	0.0082	CbGeAlD
Atomoxetine—HTR1D—brainstem—Parkinson's disease	0.000862	0.008	CbGeAlD
Atomoxetine—HTR1B—forebrain—Parkinson's disease	0.000859	0.00797	CbGeAlD
Atomoxetine—HTR2C—brainstem—Parkinson's disease	0.000853	0.00792	CbGeAlD
Atomoxetine—SLC6A3—forebrain—Parkinson's disease	0.000852	0.00791	CbGeAlD
Atomoxetine—NPY1R—brain—Parkinson's disease	0.00084	0.0078	CbGeAlD
Atomoxetine—HTR1D—forebrain—Parkinson's disease	0.000832	0.00772	CbGeAlD
Atomoxetine—HTR2C—forebrain—Parkinson's disease	0.000823	0.00765	CbGeAlD
Atomoxetine—HTR6—head—Parkinson's disease	0.000816	0.00758	CbGeAlD
Atomoxetine—SLC6A4—brainstem—Parkinson's disease	0.000809	0.00751	CbGeAlD
Atomoxetine—SLC6A4—forebrain—Parkinson's disease	0.000781	0.00725	CbGeAlD
Atomoxetine—HTR6—nervous system—Parkinson's disease	0.000774	0.00718	CbGeAlD
Atomoxetine—HTR2A—hindbrain—Parkinson's disease	0.000747	0.00693	CbGeAlD
Atomoxetine—HTR6—central nervous system—Parkinson's disease	0.000745	0.00691	CbGeAlD
Atomoxetine—HTR1B—cardiovascular system—Parkinson's disease	0.000726	0.00674	CbGeAlD
Atomoxetine—SLC6A2—brainstem—Parkinson's disease	0.000712	0.00661	CbGeAlD
Atomoxetine—HTR1D—cardiovascular system—Parkinson's disease	0.000703	0.00653	CbGeAlD
Atomoxetine—SLC6A2—forebrain—Parkinson's disease	0.000687	0.00638	CbGeAlD
Atomoxetine—CYP2D6—hindbrain—Parkinson's disease	0.00068	0.00632	CbGeAlD
Atomoxetine—Ephedrine—SLC18A2—Parkinson's disease	0.000675	0.0913	CrCbGaD
Atomoxetine—HTR2C—medulla oblongata—Parkinson's disease	0.000595	0.00552	CbGeAlD
Atomoxetine—HTR6—brain—Parkinson's disease	0.000591	0.00549	CbGeAlD
Atomoxetine—HTR1B—midbrain—Parkinson's disease	0.000567	0.00527	CbGeAlD
Atomoxetine—SLC6A3—midbrain—Parkinson's disease	0.000563	0.00522	CbGeAlD
Atomoxetine—HTR1B—spinal cord—Parkinson's disease	0.000553	0.00514	CbGeAlD
Atomoxetine—HTR1D—midbrain—Parkinson's disease	0.000549	0.0051	CbGeAlD
Atomoxetine—SLC6A3—spinal cord—Parkinson's disease	0.000549	0.0051	CbGeAlD
Atomoxetine—HTR2C—midbrain—Parkinson's disease	0.000544	0.00505	CbGeAlD
Atomoxetine—HTR2C—spinal cord—Parkinson's disease	0.000531	0.00493	CbGeAlD
Atomoxetine—SLC6A4—midbrain—Parkinson's disease	0.000515	0.00479	CbGeAlD
Atomoxetine—SLC6A4—spinal cord—Parkinson's disease	0.000503	0.00467	CbGeAlD
Atomoxetine—SLC6A2—medulla oblongata—Parkinson's disease	0.000497	0.00461	CbGeAlD
Atomoxetine—HTR1B—head—Parkinson's disease	0.000492	0.00457	CbGeAlD
Atomoxetine—SLC6A3—head—Parkinson's disease	0.000488	0.00453	CbGeAlD
Atomoxetine—HTR1D—head—Parkinson's disease	0.000476	0.00442	CbGeAlD
Atomoxetine—HTR2C—head—Parkinson's disease	0.000471	0.00438	CbGeAlD
Atomoxetine—HTR2A—embryo—Parkinson's disease	0.000467	0.00434	CbGeAlD
Atomoxetine—HTR1B—nervous system—Parkinson's disease	0.000466	0.00433	CbGeAlD
Atomoxetine—SLC6A3—nervous system—Parkinson's disease	0.000462	0.00429	CbGeAlD
Atomoxetine—HTR1D—nervous system—Parkinson's disease	0.000451	0.00419	CbGeAlD
Atomoxetine—HTR1B—central nervous system—Parkinson's disease	0.000449	0.00417	CbGeAlD
Atomoxetine—HTR2C—nervous system—Parkinson's disease	0.000447	0.00415	CbGeAlD
Atomoxetine—SLC6A4—head—Parkinson's disease	0.000447	0.00415	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—Parkinson's disease	0.000445	0.00413	CbGeAlD
Atomoxetine—SLC6A3—cerebellum—Parkinson's disease	0.000435	0.00404	CbGeAlD
Atomoxetine—HTR1D—central nervous system—Parkinson's disease	0.000435	0.00404	CbGeAlD
Atomoxetine—HTR2C—central nervous system—Parkinson's disease	0.00043	0.004	CbGeAlD
Atomoxetine—HTR2A—brainstem—Parkinson's disease	0.000428	0.00397	CbGeAlD
Atomoxetine—SLC6A4—nervous system—Parkinson's disease	0.000424	0.00393	CbGeAlD
Atomoxetine—HTR2A—forebrain—Parkinson's disease	0.000413	0.00384	CbGeAlD
Atomoxetine—SLC6A4—central nervous system—Parkinson's disease	0.000408	0.00379	CbGeAlD
Atomoxetine—SLC6A2—head—Parkinson's disease	0.000394	0.00365	CbGeAlD
Atomoxetine—CYP2D6—brainstem—Parkinson's disease	0.00039	0.00362	CbGeAlD
Atomoxetine—Benzphetamine—SLC18A2—Parkinson's disease	0.000381	0.0516	CrCbGaD
Atomoxetine—CYP2D6—forebrain—Parkinson's disease	0.000376	0.00349	CbGeAlD
Atomoxetine—SLC6A2—nervous system—Parkinson's disease	0.000373	0.00346	CbGeAlD
Atomoxetine—SLC6A2—central nervous system—Parkinson's disease	0.000359	0.00333	CbGeAlD
Atomoxetine—HTR1B—brain—Parkinson's disease	0.000356	0.00331	CbGeAlD
Atomoxetine—SLC6A3—brain—Parkinson's disease	0.000353	0.00328	CbGeAlD
Atomoxetine—HTR2A—cardiovascular system—Parkinson's disease	0.000349	0.00324	CbGeAlD
Atomoxetine—HTR1D—brain—Parkinson's disease	0.000345	0.0032	CbGeAlD
Atomoxetine—HTR2C—brain—Parkinson's disease	0.000342	0.00317	CbGeAlD
Atomoxetine—SLC6A4—brain—Parkinson's disease	0.000324	0.00301	CbGeAlD
Atomoxetine—Diphenylpyraline—SLC6A3—Parkinson's disease	0.000321	0.0435	CrCbGaD
Atomoxetine—Duloxetine—SLC6A3—Parkinson's disease	0.0003	0.0405	CrCbGaD
Atomoxetine—HTR2A—medulla oblongata—Parkinson's disease	0.000298	0.00277	CbGeAlD
Atomoxetine—SLC6A2—brain—Parkinson's disease	0.000285	0.00265	CbGeAlD
Atomoxetine—HTR2A—midbrain—Parkinson's disease	0.000273	0.00253	CbGeAlD
Atomoxetine—HTR2A—spinal cord—Parkinson's disease	0.000266	0.00247	CbGeAlD
Atomoxetine—Maprotiline—HTR7—Parkinson's disease	0.000261	0.0353	CrCbGaD
Atomoxetine—Benzatropine—SLC6A3—Parkinson's disease	0.000246	0.0333	CrCbGaD
Atomoxetine—Pseudoephedrine—MAOA—Parkinson's disease	0.000246	0.0333	CrCbGaD
Atomoxetine—HTR2A—head—Parkinson's disease	0.000237	0.0022	CbGeAlD
Atomoxetine—Maprotiline—SLC6A3—Parkinson's disease	0.000228	0.0309	CrCbGaD
Atomoxetine—HTR2A—nervous system—Parkinson's disease	0.000224	0.00208	CbGeAlD
Atomoxetine—HTR2A—central nervous system—Parkinson's disease	0.000216	0.002	CbGeAlD
Atomoxetine—CYP2D6—head—Parkinson's disease	0.000215	0.002	CbGeAlD
Atomoxetine—Pseudoephedrine—SLC6A3—Parkinson's disease	0.000212	0.0287	CrCbGaD
Atomoxetine—HTR2A—cerebellum—Parkinson's disease	0.000211	0.00196	CbGeAlD
Atomoxetine—CYP3A4—nervous system—Parkinson's disease	0.000208	0.00193	CbGeAlD
Atomoxetine—Reboxetine—CYP2D6—Parkinson's disease	0.000205	0.0277	CrCbGaD
Atomoxetine—CYP2D6—nervous system—Parkinson's disease	0.000204	0.0019	CbGeAlD
Atomoxetine—CYP3A4—central nervous system—Parkinson's disease	0.0002	0.00186	CbGeAlD
Atomoxetine—Pseudoephedrine—TNF—Parkinson's disease	0.000197	0.0267	CrCbGaD
Atomoxetine—CYP2D6—central nervous system—Parkinson's disease	0.000197	0.00183	CbGeAlD
Atomoxetine—CYP2D6—cerebellum—Parkinson's disease	0.000192	0.00178	CbGeAlD
Atomoxetine—Protriptyline—CYP2D6—Parkinson's disease	0.000188	0.0254	CrCbGaD
Atomoxetine—Modafinil—SLC6A3—Parkinson's disease	0.000182	0.0247	CrCbGaD
Atomoxetine—Duloxetine—HTR2A—Parkinson's disease	0.000172	0.0233	CrCbGaD
Atomoxetine—HTR2A—brain—Parkinson's disease	0.000171	0.00159	CbGeAlD
Atomoxetine—Maprotiline—DRD2—Parkinson's disease	0.00017	0.023	CrCbGaD
Atomoxetine—Benzphetamine—SLC6A3—Parkinson's disease	0.000158	0.0214	CrCbGaD
Atomoxetine—Duloxetine—CYP2D6—Parkinson's disease	0.000157	0.0213	CrCbGaD
Atomoxetine—CYP2D6—brain—Parkinson's disease	0.000156	0.00145	CbGeAlD
Atomoxetine—Reboxetine—ABCB1—Parkinson's disease	0.000146	0.0198	CrCbGaD
Atomoxetine—Fluoxetine—HTR2A—Parkinson's disease	0.00014	0.019	CrCbGaD
Atomoxetine—Tolterodine—CYP2D6—Parkinson's disease	0.000135	0.0182	CrCbGaD
Atomoxetine—Protriptyline—ABCB1—Parkinson's disease	0.000134	0.0182	CrCbGaD
Atomoxetine—Maprotiline—HTR2A—Parkinson's disease	0.000131	0.0177	CrCbGaD
Atomoxetine—Propranolol—HTR1A—Parkinson's disease	0.000131	0.0177	CrCbGaD
Atomoxetine—Benzatropine—CYP2D6—Parkinson's disease	0.00013	0.0175	CrCbGaD
Atomoxetine—Fluoxetine—CYP2D6—Parkinson's disease	0.000128	0.0174	CrCbGaD
Atomoxetine—Nortriptyline—HTR1A—Parkinson's disease	0.00012	0.0162	CrCbGaD
Atomoxetine—Maprotiline—CYP2D6—Parkinson's disease	0.00012	0.0162	CrCbGaD
Atomoxetine—Propafenone—CYP2D6—Parkinson's disease	0.000114	0.0155	CrCbGaD
Atomoxetine—Desipramine—SLC6A3—Parkinson's disease	0.000113	0.0153	CrCbGaD
Atomoxetine—Pseudoephedrine—CYP2D6—Parkinson's disease	0.000111	0.0151	CrCbGaD
Atomoxetine—Nortriptyline—DRD2—Parkinson's disease	0.000102	0.0138	CrCbGaD
Atomoxetine—Desipramine—HTR1A—Parkinson's disease	9.89e-05	0.0134	CrCbGaD
Atomoxetine—Nortriptyline—CYP2E1—Parkinson's disease	9.81e-05	0.0133	CrCbGaD
Atomoxetine—Fluoxetine—ABCB1—Parkinson's disease	9.17e-05	0.0124	CrCbGaD
Atomoxetine—Orphenadrine—CYP2E1—Parkinson's disease	8.58e-05	0.0116	CrCbGaD
Atomoxetine—Maprotiline—ABCB1—Parkinson's disease	8.56e-05	0.0116	CrCbGaD
Atomoxetine—Desipramine—DRD2—Parkinson's disease	8.39e-05	0.0114	CrCbGaD
Atomoxetine—Propafenone—ABCB1—Parkinson's disease	8.17e-05	0.0111	CrCbGaD
Atomoxetine—Desipramine—CYP2E1—Parkinson's disease	8.08e-05	0.0109	CrCbGaD
Atomoxetine—Nortriptyline—HTR2A—Parkinson's disease	7.88e-05	0.0107	CrCbGaD
Atomoxetine—Propranolol—CYP2D6—Parkinson's disease	7.83e-05	0.0106	CrCbGaD
Atomoxetine—Nortriptyline—CYP2D6—Parkinson's disease	7.2e-05	0.00975	CrCbGaD
Atomoxetine—Diphenhydramine—CYP2D6—Parkinson's disease	6.66e-05	0.00901	CrCbGaD
Atomoxetine—Desipramine—HTR2A—Parkinson's disease	6.49e-05	0.00877	CrCbGaD
Atomoxetine—Methadone—CYP2D6—Parkinson's disease	6.43e-05	0.0087	CrCbGaD
Atomoxetine—Desipramine—CYP2D6—Parkinson's disease	5.93e-05	0.00802	CrCbGaD
Atomoxetine—Propranolol—ABCB1—Parkinson's disease	5.59e-05	0.00757	CrCbGaD
Atomoxetine—Methadone—ABCB1—Parkinson's disease	4.59e-05	0.00621	CrCbGaD
Atomoxetine—Desipramine—ABCB1—Parkinson's disease	4.24e-05	0.00573	CrCbGaD
Atomoxetine—CYP2C19—Metabolism—NDUFB11—Parkinson's disease	2.44e-05	0.000152	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD1—Parkinson's disease	2.41e-05	0.00015	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—ADRBK1—Parkinson's disease	2.4e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GRK5—Parkinson's disease	2.4e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—HTR1A—Parkinson's disease	2.38e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FGF20—Parkinson's disease	2.38e-05	0.000148	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—OMD—Parkinson's disease	2.36e-05	0.000147	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TALDO1—Parkinson's disease	2.36e-05	0.000147	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FGF20—Parkinson's disease	2.36e-05	0.000147	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TAC1—Parkinson's disease	2.35e-05	0.000146	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PENK—Parkinson's disease	2.35e-05	0.000146	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAG—Parkinson's disease	2.35e-05	0.000146	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD3—Parkinson's disease	2.33e-05	0.000145	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GCH1—Parkinson's disease	2.32e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD2—Parkinson's disease	2.32e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HTR7—Parkinson's disease	2.32e-05	0.000145	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	2.32e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FGF20—Parkinson's disease	2.31e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADORA2A—Parkinson's disease	2.3e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD1—Parkinson's disease	2.3e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EDN1—Parkinson's disease	2.29e-05	0.000143	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	2.29e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADORA2A—Parkinson's disease	2.29e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EDN1—Parkinson's disease	2.27e-05	0.000142	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NDUFB11—Parkinson's disease	2.24e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADORA2A—Parkinson's disease	2.24e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD3—Parkinson's disease	2.23e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EDN1—Parkinson's disease	2.23e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—HTR2A—Parkinson's disease	2.21e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—HTR2A—Parkinson's disease	2.19e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—ADRBK1—Parkinson's disease	2.18e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HTR1A—Parkinson's disease	2.16e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GRM4—Parkinson's disease	2.15e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PDYN—Parkinson's disease	2.15e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—HTR2A—Parkinson's disease	2.14e-05	0.000134	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GCH1—Parkinson's disease	2.14e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TAC1—Parkinson's disease	2.13e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—INSR—Parkinson's disease	2.13e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—INSR—Parkinson's disease	2.11e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD2—Parkinson's disease	2.11e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HTR7—Parkinson's disease	2.11e-05	0.000131	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	2.1e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD1—Parkinson's disease	2.09e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—ADRBK1—Parkinson's disease	2.08e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—FBP1—Parkinson's disease	2.07e-05	0.000129	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—DBH—Parkinson's disease	2.07e-05	0.000129	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GBA—Parkinson's disease	2.07e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—INSR—Parkinson's disease	2.07e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PENK—Parkinson's disease	2.04e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAG—Parkinson's disease	2.04e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD3—Parkinson's disease	2.02e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GFAP—Parkinson's disease	2.02e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—HTR7—Parkinson's disease	2.02e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD2—Parkinson's disease	2.02e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FGB—Parkinson's disease	2.01e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HTR2A—Parkinson's disease	2e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR1A—Parkinson's disease	2e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GRM5—Parkinson's disease	1.99e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FGB—Parkinson's disease	1.99e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HTR2A—Parkinson's disease	1.99e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL6—Parkinson's disease	1.99e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR1A—Parkinson's disease	1.98e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TAC1—Parkinson's disease	1.97e-05	0.000123	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TAC1—Parkinson's disease	1.95e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FGB—Parkinson's disease	1.95e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HTR2A—Parkinson's disease	1.95e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR1A—Parkinson's disease	1.94e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD1—Parkinson's disease	1.93e-05	0.00012	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD1—Parkinson's disease	1.92e-05	0.000119	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TAC1—Parkinson's disease	1.91e-05	0.000119	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—DBH—Parkinson's disease	1.91e-05	0.000119	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—FBP1—Parkinson's disease	1.91e-05	0.000119	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GBA—Parkinson's disease	1.91e-05	0.000119	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CASP3—Parkinson's disease	1.9e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ADRBK1—Parkinson's disease	1.89e-05	0.000118	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL6—Parkinson's disease	1.89e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD1—Parkinson's disease	1.88e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD3—Parkinson's disease	1.87e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PDYN—Parkinson's disease	1.86e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—EDN1—Parkinson's disease	1.86e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD3—Parkinson's disease	1.85e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HTR7—Parkinson's disease	1.83e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD2—Parkinson's disease	1.83e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD3—Parkinson's disease	1.82e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.77e-05	0.00011	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GFAP—Parkinson's disease	1.75e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGF20—Parkinson's disease	1.75e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADRBK1—Parkinson's disease	1.75e-05	0.000109	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MAPK8—Parkinson's disease	1.74e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADRBK1—Parkinson's disease	1.73e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GRM5—Parkinson's disease	1.73e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADRBK1—Parkinson's disease	1.7e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADORA2A—Parkinson's disease	1.7e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD2—Parkinson's disease	1.69e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR7—Parkinson's disease	1.69e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EDN1—Parkinson's disease	1.69e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD2—Parkinson's disease	1.68e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR7—Parkinson's disease	1.68e-05	0.000105	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MCCC1—Parkinson's disease	1.64e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ND3—Parkinson's disease	1.64e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR7—Parkinson's disease	1.64e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD2—Parkinson's disease	1.64e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HTR2A—Parkinson's disease	1.63e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—EDN1—Parkinson's disease	1.61e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—INSR—Parkinson's disease	1.57e-05	9.76e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—OMD—Parkinson's disease	1.55e-05	9.64e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TALDO1—Parkinson's disease	1.55e-05	9.64e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.54e-05	9.59e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—DDC—Parkinson's disease	1.52e-05	9.48e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGF20—Parkinson's disease	1.52e-05	9.47e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGB—Parkinson's disease	1.48e-05	9.23e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HTR2A—Parkinson's disease	1.48e-05	9.2e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADORA2A—Parkinson's disease	1.47e-05	9.19e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR1A—Parkinson's disease	1.47e-05	9.18e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	1.47e-05	9.14e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EDN1—Parkinson's disease	1.47e-05	9.14e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TAC1—Parkinson's disease	1.45e-05	9.04e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTA4—Parkinson's disease	1.44e-05	8.96e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD1—Parkinson's disease	1.42e-05	8.86e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	1.42e-05	8.84e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF2—Parkinson's disease	1.42e-05	8.83e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF2—Parkinson's disease	1.41e-05	8.77e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—DDC—Parkinson's disease	1.4e-05	8.72e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GCH1—Parkinson's disease	1.4e-05	8.72e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF2—Parkinson's disease	1.38e-05	8.58e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD3—Parkinson's disease	1.38e-05	8.58e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1R—Parkinson's disease	1.37e-05	8.54e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—INSR—Parkinson's disease	1.36e-05	8.48e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1R—Parkinson's disease	1.36e-05	8.48e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EDN1—Parkinson's disease	1.35e-05	8.44e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EDN1—Parkinson's disease	1.34e-05	8.38e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1R—Parkinson's disease	1.33e-05	8.3e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTA4—Parkinson's disease	1.32e-05	8.24e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EDN1—Parkinson's disease	1.32e-05	8.2e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PLA2G6—Parkinson's disease	1.29e-05	8.06e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADRBK1—Parkinson's disease	1.29e-05	8.02e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGB—Parkinson's disease	1.28e-05	8.01e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MAOB—Parkinson's disease	1.28e-05	7.98e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HTR1A—Parkinson's disease	1.28e-05	7.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TAC1—Parkinson's disease	1.26e-05	7.85e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GBA—Parkinson's disease	1.25e-05	7.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DBH—Parkinson's disease	1.25e-05	7.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—FBP1—Parkinson's disease	1.25e-05	7.77e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR7—Parkinson's disease	1.24e-05	7.76e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD2—Parkinson's disease	1.24e-05	7.76e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NGF—Parkinson's disease	1.24e-05	7.76e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NGF—Parkinson's disease	1.23e-05	7.7e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD1—Parkinson's disease	1.23e-05	7.7e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	1.22e-05	7.6e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NGF—Parkinson's disease	1.21e-05	7.54e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD3—Parkinson's disease	1.2e-05	7.45e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	1.19e-05	7.42e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR2A—Parkinson's disease	1.18e-05	7.38e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MAOB—Parkinson's disease	1.18e-05	7.34e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR2A—Parkinson's disease	1.17e-05	7.33e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR2A—Parkinson's disease	1.15e-05	7.17e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRBK1—Parkinson's disease	1.12e-05	6.96e-05	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL6—Parkinson's disease	1.11e-05	6.95e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APOE—Parkinson's disease	1.1e-05	6.86e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APOE—Parkinson's disease	1.09e-05	6.81e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD2—Parkinson's disease	1.08e-05	6.74e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HTR7—Parkinson's disease	1.08e-05	6.74e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOE—Parkinson's disease	1.07e-05	6.67e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF2—Parkinson's disease	1.04e-05	6.51e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1R—Parkinson's disease	1.01e-05	6.29e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EDN1—Parkinson's disease	9.97e-06	6.22e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2D6—Parkinson's disease	9.51e-06	5.93e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—INS—Parkinson's disease	9.4e-06	5.86e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CTGF—Parkinson's disease	9.34e-06	5.82e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—INS—Parkinson's disease	9.33e-06	5.82e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NGF—Parkinson's disease	9.16e-06	5.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DDC—Parkinson's disease	9.15e-06	5.7e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—INS—Parkinson's disease	9.14e-06	5.7e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF2—Parkinson's disease	9.06e-06	5.65e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1R—Parkinson's disease	8.76e-06	5.46e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR2A—Parkinson's disease	8.72e-06	5.44e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2E1—Parkinson's disease	8.7e-06	5.43e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EDN1—Parkinson's disease	8.65e-06	5.4e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTA4—Parkinson's disease	8.64e-06	5.39e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NQO1—Parkinson's disease	8.6e-06	5.37e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CTGF—Parkinson's disease	8.59e-06	5.36e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TH—Parkinson's disease	8.48e-06	5.29e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYCS—Parkinson's disease	8.14e-06	5.08e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—Parkinson's disease	8.11e-06	5.05e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	8e-06	4.99e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NGF—Parkinson's disease	7.95e-06	4.96e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NQO1—Parkinson's disease	7.91e-06	4.94e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TH—Parkinson's disease	7.8e-06	4.86e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	7.78e-06	4.85e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MAOB—Parkinson's disease	7.7e-06	4.8e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYCS—Parkinson's disease	7.49e-06	4.67e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—COMT—Parkinson's disease	7.21e-06	4.5e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—Parkinson's disease	7.18e-06	4.48e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MAOA—Parkinson's disease	7.16e-06	4.46e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMOX1—Parkinson's disease	7.08e-06	4.41e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—Parkinson's disease	7.04e-06	4.39e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—Parkinson's disease	7e-06	4.37e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—Parkinson's disease	6.96e-06	4.34e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—Parkinson's disease	6.95e-06	4.33e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—INS—Parkinson's disease	6.92e-06	4.32e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—Parkinson's disease	6.9e-06	4.3e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—Parkinson's disease	6.8e-06	4.24e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCB1—Parkinson's disease	6.79e-06	4.24e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—Parkinson's disease	6.76e-06	4.21e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—COMT—Parkinson's disease	6.63e-06	4.14e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	6.6e-06	4.12e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—Parkinson's disease	6.59e-06	4.11e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MAOA—Parkinson's disease	6.58e-06	4.11e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	6.51e-06	4.06e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK8—Parkinson's disease	6.43e-06	4.01e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK8—Parkinson's disease	6.39e-06	3.98e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GPX1—Parkinson's disease	6.32e-06	3.94e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK8—Parkinson's disease	6.25e-06	3.9e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	6.25e-06	3.9e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	6.07e-06	3.78e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—INS—Parkinson's disease	6.01e-06	3.75e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—Parkinson's disease	5.83e-06	3.63e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GPX1—Parkinson's disease	5.81e-06	3.62e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	5.72e-06	3.57e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CTGF—Parkinson's disease	5.62e-06	3.5e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—Parkinson's disease	5.43e-06	3.38e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	5.36e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	5.23e-06	3.26e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NQO1—Parkinson's disease	5.17e-06	3.23e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—Parkinson's disease	5.16e-06	3.22e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—Parkinson's disease	5.12e-06	3.19e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TH—Parkinson's disease	5.1e-06	3.18e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—Parkinson's disease	4.99e-06	3.11e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYCS—Parkinson's disease	4.9e-06	3.05e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK8—Parkinson's disease	4.74e-06	2.95e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—INS—Parkinson's disease	4.64e-06	2.89e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—Parkinson's disease	4.48e-06	2.79e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—Parkinson's disease	4.45e-06	2.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—COMT—Parkinson's disease	4.34e-06	2.7e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—Parkinson's disease	4.32e-06	2.69e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MAOA—Parkinson's disease	4.31e-06	2.68e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—INS—Parkinson's disease	4.26e-06	2.66e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMOX1—Parkinson's disease	4.26e-06	2.65e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK8—Parkinson's disease	4.11e-06	2.57e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—Parkinson's disease	4.11e-06	2.56e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCB1—Parkinson's disease	4.08e-06	2.55e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—Parkinson's disease	4.08e-06	2.54e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—Parkinson's disease	3.99e-06	2.49e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—Parkinson's disease	3.97e-06	2.47e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPX1—Parkinson's disease	3.8e-06	2.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—Parkinson's disease	3.5e-06	2.19e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—Parkinson's disease	3.26e-06	2.03e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—Parkinson's disease	3.03e-06	1.89e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—INS—Parkinson's disease	2.79e-06	1.74e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—Parkinson's disease	2.63e-06	1.64e-05	CbGpPWpGaD
